Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. reports clinical and corporate developments as a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody combining an EGFR-directed monoclonal antibody with a domain that binds human TGF-beta, with company updates focused on first-line recurrent or metastatic HPV-negative HNSCC and the FORTIFI-HN01 pivotal trial.
Recurring news also includes quarterly financial results, business updates, public equity financing, common stock and pre-funded warrant offerings, Nasdaq inducement grants, and executive appointments tied to clinical development, medical affairs and commercial readiness.
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, has announced the pricing of its upsized initial public offering. The company is offering 17,500,000 shares of common stock at $18.00 per share. Trading is expected to begin on the Nasdaq Global Market on September 13, 2024, under the ticker symbol 'BCAX'. The offering is set to close on September 16, 2024.
Bicara has granted underwriters a 30-day option to purchase up to an additional 2,625,000 shares. The gross proceeds are expected to be approximately $315.00 million, excluding any exercise of the underwriters' option. Morgan Stanley, TD Cowen, Cantor, and Stifel are acting as joint bookrunners for the offering.